Short Interest in Ampliphi Biosciences Corp (APHB) Declines By 14.8%

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 1,115,468 shares, a drop of 14.8% from the October 31st total of 1,308,517 shares. Based on an average daily volume of 247,174 shares, the short-interest ratio is presently 4.5 days. Currently, 13.0% of the shares of the company are sold short.

Separately, HC Wainwright set a $5.00 target price on shares of Ampliphi Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 15th.

Ampliphi Biosciences (NYSEAMERICAN:APHB) traded down $0.04 on Wednesday, reaching $1.02. 119,965 shares of the company were exchanged, compared to its average volume of 470,287. Ampliphi Biosciences has a 52-week low of $0.67 and a 52-week high of $6.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/ampliphi-biosciences-corp-aphb-short-interest-down-14-8-in-november.html.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply